PrimeVigilance and PharmInvent combine to create leading, international full service pharmacovigilance, medical information and regulatory service provider
pharmafile | November 29, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
PrimeVigilance and PharmInvent are pleased to announce that they are now working together as an integrated service provider following the acquisition of PharmInvent by Ergomed plc, the owner of PrimeVigilance.
The companies will continue to trade under their current names and there will be no changes to any of the existing client arrangements, including staffing or any other business relationships.
There is however clear intention to share expertise and ensure that existing clients continue to receive the highest standards of service and also to introduce new services or expertise where appropriate and also to attract new clients from across the globe. The combination of PharmInvent and PrimeVigilance creates one of the world’s largest specialist drug safety service providers with over 300 highly qualified staff based in the UK, Europe and USA. The combined range of service offerings is excellent with both companies benefitting from the additional skills that the other party brings to the enlarged business.
Neil Clark, Chief Executive Officer of PrimeVigilance Ltd, commented: “This synergistic combination of PharmInvent with PrimeVigilance creates a business with a market-leading position in the provision of outsourced pharmacovigilance services for clients developing or selling drug products across the world. The enhanced service offering and mutual focus on high quality will ensure that existing and new clients continue to receive the best advice and service”.
Jan Petracek MD, Chief Executive Officer of PharmInvent, said: “These are very exciting times for PharmInvent. We have spent the last six years building our business and reputation and now look forward to significantly leveraging our position working alongside PrimeVigilance. Together, our skills will allow us to seize significant new opportunities as well as expand our offering to our existing customer base. “
PharmInvent will continue to be led by its founders, Dr Jan Petracek and Dr Martin Votava. Dr Petracek was formerly a Head of the Risk Management Section at the European Medicines Agency (EMA), while Dr Votava represented the Czech Republic in the Committee for Medicinal Products for Human Use at the EMA.
CEO of PharmInvent, Dr Jan Petracek, will join the Board of PrimeVigilance. Neil Clark, CEO of PrimeVigilance, will join the Board of PharmInvent.
In addition, Dr Jan Petracek has been appointed as non-executive director and President of PrimeVigilance.
